Aleksandra Hec-Gałązka

Aleksandra Hec-Gałązka

Auto-generated profile, based on publicly available information

Aleksandra Hec-Gałązka

Jagiellonian University, Doctoral School of Exact and Natural Sciences, prof. S. Łojasiewicza 11, 30-348 Krakow, Poland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
AHAleksandra Hec-Gałązka
Aleksandra Hec-Gałązka
UTUrszula Tyrcha
Urszula Tyrcha
JBJan Barczyński
Jan Barczyński
PBPrzemyslaw Bielski
Przemyslaw Bielski
MMMichał Mikitiuk
Michał Mikitiuk
THTad Holak
Tad Holak
Therapeutic antibodies directed against either programmed cell death-1 protein (PD-1) or its ligand PD-L1 have demonstrated efficacy in the treatment of various cancers. In contrast with antibodies, small molecules have the potential for increased tissue penetration; better pharmacology; and therefore, improved antitumor activity. A series of nonsymmetric C2 inhibitors were synthesized and evaluated for PD-1/PD-L1 interaction inhibition. These compounds induced PD-L1 dimerization and effectively blocked PD-L1/PD-1 interaction in a homogeneous time-resolved fluorescence (HTRF) assay with most inhibitors exhibiting IC50 values in the single-digit nM range and below. Their high inhibitory potency was also demonstrated in a cell-based coculture PD-1 signaling assay where 2 exhibited an EC50 inhibitory activity of 21.8 nM, which approached that of the PD-L1 antibody durvalumab (EC50 = 0.3-1.8 nM). Structural insight into how these inhibitors interact with PD-L1 was gained by using NMR and X-ray cocrystal structure studies. These data support further preclinical evaluation of these compounds as antibody alternatives.